Capillary Electrophoresis Market Analysis

Product Segment Analysis

Based on the product, the capillary electrophoresis systems segment is expected to garner the largest revenue share of 48.6% during the discussed timeframe. The dominance of the segment is effectively attributable to the need for advanced, automated, and high-throughput systems to meet the demanding requirements of modern laboratories. In May 2022, QIAGEN introduced the QIAxcel Connect, which is a high-resolution, high-sensitivity capillary electrophoresis instrument designed to deliver powerful nucleic acid analysis with plug-and-play simplicity and low operating costs.

End user Segment Analysis

In terms of end user pharmaceutical & biotechnology companies segment is projected to attain a significant share of 42.7% by the end of 2035. The extensive use of CE for quality control and characterization of biologics, especially monoclonal antibodies, is the key factor behind this leadership. Besides the regulatory agencies' mandate for rigorous analysis of purity, charge variants, and glycan profiles to ensure safety and efficacy positions the segment is positioned as a gold standard to generate revenue in this field.

Application Segment Analysis

Based on the application drug discovery & development segment is likely to capture a share of 35.4% during the analyzed timeframe. The growth in the segment is highly subject to the heightened demand for CE in biopharmaceutical R&D, especially for protein analysis and genetic analysis. In January 2023, Bio-Techne Corporation introduced the MauriceFlex system under its ProteinSimple brand, thereby expanding the capabilities of capillary electrophoresis for protein charge variant analysis. The firm also stated that the system efficiently combines routine cIEF and CE-SDS assays with cIEF-based fractionation, enabling same-day analysis of protein charge variants.

Our in-depth analysis of the global market includes the following segments: